Poseida Therapeutics is a spin out of Transposagen Biopharmaceuticals that utilizes best-in-class, proprietary genome editing technologies to develop targeted, life-saving therapeutics in areas of high unmet medical need. It has demonstrated proof-of-principle that validates the potential of its differentiated genome engineering technologies and their therapeutic applications. The company's technology platforms have broad applicability and Poseida’s long-term goal is to apply its proprietary gene editing technologies to a broad range of human diseases.